Skip to main content
. 2019 Mar 21;4(6):e125294. doi: 10.1172/jci.insight.125294

Figure 4. CD44v6+ compared with CD44v6– sphere-derived cancer stem cells have higher stemness.

Figure 4

(A) FACS analysis of CD44v6-positive and -negative sphere-derived cancer stem cells (SDCSCs) derived from a HCT116 cell line. (B) Spheroid-forming capacity of HCT116- and HT29-derived CD44v6+ and CD44v6– SDCSCs (n = 16, Mann-Whitney U test). (C) Spheroid-forming ability of HCT116 (left) and HT29 (right) CD44v6+ and CD44v6– SDCSCs in the presence of 5FU (top) and oxaliplatin (bottom; n = 6 per time point, Mann-Whitney U test). *P < 0.05, **P < 0.01, ***P < 0.001.